Hepatitis C Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Hepatitis C Market is projected to expand from USD 9.32 Billion in 2025 to USD 13.15 Billion by 2031, reflecting a compound annual growth rate of 5.91%. This sector encompasses the manufacturing and distribution of diagnostic tools and therapeutic agents, specifically Direct Acting Antivirals utilized to manage and eradicate hepatitis C infections. The market's upward trajectory is primarily fueled by the rising global disease burden and international directives for viral elimination, which promote government-sponsored screening and treatment programs. Furthermore, the safety and high success rates of modern antiviral regimens enhance patient compliance and broaden the treatable demographic, addressing the needs of the 50 million individuals reported by the World Health Organization in 2024 to be living with chronic hepatitis C.

Despite these positive indicators, the market encounters substantial obstacles due to the prohibitive costs of advanced therapies, which limit availability in developing nations with high price sensitivity. This financial hurdle is compounded by low rates of diagnosis, as inadequate healthcare infrastructure in these areas fails to identify asymptomatic carriers. Consequently, a significant number of infected individuals remain without treatment, a situation that prevents the market from reaching its full potential and decelerates global elimination initiatives.

Market Drivers

The execution of Government-Led Disease Elimination Programs acts as a crucial market catalyst, with nations implementing strategies to align with international health objectives. These extensive public health structures require significant procurement of diagnostics and medications, establishing a reliable commercial channel for industry participants. The United Kingdom exemplifies success in this area, proving the effectiveness of state-managed efforts; the Viral Hepatitis Prevention Board's November 2024 analysis in the 'HCV in England report 2024' indicates that the national elimination strategy reduced hepatitis C-related mortality to 0.41 per 100,000 people, exceeding World Health Organization targets and demonstrating the value of funded interventions.

Complementing these policies, the broad uptake of Advanced Direct-Acting Antiviral Therapies propels market expansion by facilitating rapid and effective cures for diagnosed patients. The superior safety profile and simplified dosing schedules of these modern treatments have markedly enhanced linkage-to-care statistics, resulting in increased treatment volumes worldwide. This demand is highlighted by the British Liver Trust's April 2025 'Hepatitis C in England 2024' report, which noted that 96.1% of diagnosed individuals connected to care began treatment. Nevertheless, the global disease burden remains a primary driver of demand; the Centers for Disease Control and Prevention reported in their July 2025 'Global Viral Hepatitis' update that approximately 1 million new infections occurred globally in the previous year, emphasizing the persistent need for market solutions.

Market Challenges

The substantial acquisition costs associated with advanced antiviral therapies act as a major constraint on market growth, especially within developing economies where healthcare resources are scarce. These elevated pricing models often surpass the financial limits of public health systems and individual patients, thereby restricting the quantity of treatments distributed. Such economic barriers hinder the market's ability to leverage the high disease prevalence in these regions, leading to significant revenue forfeiture and restricted market entry in areas that otherwise demonstrate a strong need for medical intervention.

Additionally, the absence of robust healthcare infrastructure aggravates this challenge by impeding the identification of the infected population. Insufficient diagnostic capabilities mean that a vast number of patients remain unaware of their condition, preventing them from accessing essential therapies. According to the World Health Organization, only 36% of individuals living with hepatitis C worldwide were diagnosed in 2024. This substantial diagnosis gap effectively diminishes the size of the addressable market, as the majority of potential candidates for therapeutic agents remain undetected and untreated, which directly stalls overall market expansion.

Market Trends

The Decentralization of Care to Community Pharmacies is reshaping service delivery by moving treatment initiation from centralized hospitals to readily accessible local drugstores. This trend helps overcome infrastructure limitations by enabling pharmacists to administer screenings and prescribe direct-acting antivirals, effectively engaging patients who might otherwise be lost in traditional care pathways. The National Institutes of Health's October 2025 study, 'Pharmacist Involvement in Hepatitis C Management,' validates the efficacy of this model in bridging the gap between diagnosis and cure, revealing that pharmacist-led initiatives achieved a therapy initiation rate of 66.5%, which is significantly higher than standard referral methods. By streamlining the patient experience, this approach improves adherence and broadens the market reach within high-prevalence communities.

Concurrently, the Adoption of Digital Test-to-Treat Platforms is increasing market penetration by resolving issues of geographical isolation through virtual healthcare interactions. These integrated telemedicine systems enable providers to diagnose conditions and prescribe curative treatments remotely, eliminating the need for physical clinic visits in underserved areas.

The impact on engaging hard-to-reach populations is evident in Oregon Health & Science University's November 2024 report, 'Telehealth plus local peer support boosts treatment success for hepatitis C in rural patients,' which found that 85% of patients referred to telehealth services successfully enrolled in treatment compared to just 12% in the control group. This high uptake demonstrates that digital platforms are essential for stimulating demand in regions lacking adequate medical facilities.

Key Players Profiled in the Hepatitis C Market

• GlaxoSmithKline PLC
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Bayer AG
• Merck & Co., Inc.
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company B

Report Scope

In this report, the Global Hepatitis C Market has been segmented into the following categories:

Hepatitis C Market, by Type:

• Acute Hepatitis C
• Chronic Hepatitis C
• Others

Hepatitis C Market, by Treatment:

• Antiviral Drugs
• Vaccine
• Immune Modulator Drugs
• Surgery
• Others

Hepatitis C Market, by Diagnosis:

• Liver Biopsy
• Blood Tests
• Imaging Tests
• Others

Hepatitis C Market, by Route of Administration:

• Oral
• Parenteral
• Others

Hepatitis C Market, by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hepatitis C Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis C Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.